The quest for prognostic molecular markers in prostatic
carcinoma is still in progress. Many proteins have already
been screened by immunohistochemistry aiming to find the
most reliable indicator of progressive disease. We substantiate
the prognostic value of 3 tissue markers, the cell cycle proteins
p27 (kip I) and MIS-1 and the cell adhesion protein CD44s.
Materials and Methods: We studied selected 100 patients
with prostatic carcinoma in the period from 1999 to 2004 who
did not receive radiation, hormonal therapy, or chemotherapy
before surgery. Representative tumor sections were immunohistochemically
stained with antibodies against p27 (kipl),
MIB-1 (Ki-67) and CD44s and assessed in a semiquantitative
manner. Gleason score and pathological tumor stage were
recorded. We have evaluated the relationship between expression
of these proteins and clinicopathological parameters such
as tumor nuclear grade, pathological stage. Gleason score and
lymph node invasion. All variables were correlated with
clinical progression and disease specific survival on univariate
and multivariate analyses.
The present study was undertaken to investigate the degree
of expression of CD44. P27 and Ki-67 (MIS-1) by immunohistochemistry
us a predictor of the clinical behavior in
prostatic carcinoma.
Results: Statistically highly significant inverse relationship
(p<0.01) was seen between reduced CD44 expression and
tumor stage. Gleason sum score and lymph node invasion.
statistically significant direct relationship (p<0.05) was seen
between MIS- I and p27 expression in one side and tumor
grade, stage and Gleason sum score on the other side.
Conclusions: This study highlighted the role of CD44,
MIS-1 and p27 immunoreactivity in prostate cancer progression,
they could be used as valuable prognostic parameters
in prostate cancer and their associated expression may provide
additional prognostic advantage for undetermined cases of
aggressive potentiality. Reduced p27 (kip I) and increased
MIS- I expression are independent predictors of poor outcome
in prostate cancer. Decreased expression of CD44s yields
additional information in predicting poor clinical outcome.
These tissue markers may identify patients clinical outcome
that may benefit from adjuvant therapy |
